NanoVibronix, a medical technology company specializing in non-invasive therapeutic devices, completed its acquisition of ENvue Medical Holdings, a privately-held provider of enteral feeding solutions.
The company said the acquisition should strengthen the combined companies' market position in enteral feeding technology and therapeutic medical devices, as ENvue’s proprietary technology aligns with the company’s commitment to patient safety and advanced medical solutions.
"This transaction represents a transformational opportunity for NanoVibronix and our shareholders. ENvue Medical has developed an innovative solution that directly addresses critical patient safety challenges in enteral feeding, and we are excited to integrate their technology into our portfolio. Together, we are positioned to accelerate growth, improve patient outcomes and create long-term value for our shareholders," said NanoVibronix CEO Brian Murphy.
The acquisition of ENvue was structured as a stock-for-stock transaction pursuant to which all of ENvue’s outstanding equity interests were exchanged based on a fixed exchange ratio. The total value of the transaction was not disclosed.
The acquisition was approved by both boards and stockholders of ENvue and was consummated on February 14, 2025.
